Pembrolizumab is approved by FDA as adjuvant treatment for non-small cell lung cancer

Keytruda for NSCLC

Share This Post

Feb 2023: For stage IB (T2a 4 cm), stage II, or stage IIIA non-small cell lung cancer, the Food and Drug Administration (FDA) approved pembrolizumab (Keytruda, Merck) as adjuvant therapy after resection and platinum-based chemotherapy (NSCLC).

KEYNOTE-091 (NCT02504372), a multicenter, randomised, triple-blind, placebo-controlled trial, assessed efficacy. Patients had not undergone chemotherapy or neoadjuvant radiation. Every three weeks for up to a year, patients were randomised (1:1) to receive either pembrolizumab 200 mg or a placebo intravenously. The location of the world and adjuvant chemotherapy were stratification variables. 1010 (86%) of the 1177 randomised patients who underwent full resection also underwent adjuvant platinum-based treatment.

Disease-free survival, as determined by the investigator, was the primary effectiveness outcome measure (DFS). The trial’s primary goal was met when it showed a statistically significant increase in DFS across the board. The DFS hazard ratio was 1.25 (95% CI: 0.76, 2.05) in an exploratory subgroup analysis of the 167 patients who did not receive adjuvant treatment. The median DFS for patients who had adjuvant chemotherapy was 34.9 months in the pembrolizumab arm (95% CI: 28.6, not reached) and 58.7 months in the pembrolizumab arm (95% CI: 39.2, not reached).

Except for hypothyroidism (22%), hyperthyroidism (11%), and pneumonitis (7%), the adverse events seen in KEYNOTE-091 were mainly similar to those seen in other patients with NSCLC receiving KEYTRUDA as a single drug. There were two fatal myocarditis adverse reactions.

The suggested dose of pembrolizumab is 200 mg every three weeks or 400 mg every six weeks, up to a maximum of 12 months, or until the disease recurs or there is intolerable toxicity.

Project Orbis, an initiative of the FDA Oncology Center of Excellence, was used to carry out this review. International partners can simultaneously submit and review oncology medications using the infrastructure provided by Project Orbis. FDA worked together on this review with the Therapeutic Goods Administration (TGA) of Australia, Health Canada, and Swissmedic. At the other regulatory organizations, the application reviews are still proceeding.

View full prescribing information for Keytruda.

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Claudin18.2-targeted CAR-T cell therapy brings complete remission in advanced pancreatic cancer patient A case report
CAR T-Cell therapy

Claudin18.2-targeted CAR-T cell therapy brings complete remission in advanced pancreatic cancer patient : A case report

Claudin18.2-targeted CAR-T cell therapy has shown remarkable potential in treating advanced pancreatic cancer, as highlighted in a recent case report. This innovative approach led to complete remission in a patient with advanced disease, underscoring the promise of targeted immunotherapy. By leveraging the specific expression of Claudin18.2 on cancer cells, this therapy offers a precision-based treatment, heralding a new era in pancreatic cancer management with significant clinical implications.

What is the treatment after BCMA CAR T failed in RR multiple myeloma cases
CAR T-Cell therapy

What is the treatment after BCMA CAR T failed in R/R multiple myeloma cases?

For people with relapsed or refractory multiple myeloma, BCMA CAR T-cell therapy might not work. Other treatments, such as bispecific antibodies, other CAR T-cell therapies that target different antigens, and combination regimens with immunomodulatory drugs, proteasome inhibitors, and monoclonal antibodies, can still be used. OriCAR-017 is another immunotherapy that is under trial and is expected to be launched soon. Clinical trials offer experimental treatments, providing access to novel therapies. Tailored approaches based on patient-specific factors and emerging research are crucial for improving outcomes in this challenging scenario.

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

Start chat
We Are Online! Chat With Us!
Scan the code
Hello,

Welcome to CancerFax !

CancerFax is a pioneering platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies like CAR T-Cell therapy, TIL therapy, and clinical trials worldwide.

Let us know what we can do for you.

1) Cancer treatment abroad?
2) CAR T-Cell therapy
3) Cancer vaccine
4) Online video consultation
5) Proton therapy